<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361866</url>
  </required_header>
  <id_info>
    <org_study_id>GC1107_AD_P3</org_study_id>
    <nct_id>NCT02361866</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults</brief_title>
  <official_title>Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness(immunogeneicity) and safety of
      'GC1107' administered intramuscularly in healthy Adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double blind, multicenter, phaseⅢ study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>seroprotection rate of diphtheria and tetanus</measure>
    <time_frame>28days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT (Geometric Mean Titer)</measure>
    <time_frame>28days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boosting response of diphtheria and tetanus compared participants with before and after the injection</measure>
    <time_frame>28days</time_frame>
    <description>Boosting response is defined as more 4 times increase of the antibody titer after the injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>solicited adverse events</measure>
    <time_frame>7days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unsolicited adverse events</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate according to the respective age group</measure>
    <time_frame>28days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT according to the respective age group</measure>
    <time_frame>28days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">376</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>GC1107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, intramuscular, a single dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetanus and Diphtheria(Td vaccine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5ml, intramuscular, a single dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC1107</intervention_name>
    <description>0.5 ml, Intramuscular, single dose(day0)</description>
    <arm_group_label>GC1107</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus and Diphtheria(Td vaccine)</intervention_name>
    <description>0.5ml, Intramuscular, single dose(day0) only applicable step1</description>
    <arm_group_label>Tetanus and Diphtheria(Td vaccine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy Korean adults (age: over 18 years)

          -  who got the basic vaccination of DTP(Diphtheria, tetanus, pertussis) in the past

          -  Subjects willing to provide written informed consent and able to comply with the
             requirements for the study

        Exclusion Criteria:

          -  subjects who have already got the additional vaccination of Td within 5 years

          -  subjects with antitoxin of diphtheria and tetanus ≥1.0 IU/mL (ELISA)

               -  only applicable in step I

          -  subjects who have not recovered from the acute disease within 2 weeks

          -  subjects who have the medical history of allergic disease related to the components of
             investigational drug

          -  who got the treatment of blood product and immunoglobulin product within 3 months

          -  females who are pregnant

          -  females who are breastfeeding

          -  subjects who are infected from the diphtheria and tetanus

          -  subjects who have experienced the severe adverse events for the diphtheria and tetanus
             vaccination

          -  Subjects who are scheduled to participate in other clinical trial studies during the
             study

          -  Subjects who have participated in any other clinical trials within 4 weeks of the
             administration of the study

          -  Those who take the other medicine that affects this study or are vaccinated other
             vaccines

          -  Subject who have received adrenocortical hormones or immunosuppressive drug within
             4weeks of enrollment

          -  Subjects with a history of chronic disease obstacles to the study.

          -  Subjects who have episode of acute febrile (at least 37.4) after injection of vaccine
             during the study

          -  Subject who have plan of operation during the study.

          -  Individuals with other clinically significant medical or psychological condition who
             are considered by the investigator to be ineligible for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JungHyeon Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Incheon St. Mary's Hospital Catholic University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Incheon St. Mary's Hospital Catholic Univ.</name>
      <address>
        <city>Incheon</city>
        <state>Bupyeong 6-dong, Bupyeong-gu,</state>
        <zip>1544-9004</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2015</study_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

